Fewer gastrointestinal side effects, possibility of oral administration…Early clinical findings, including weight loss benefits, are to be unveiled at ADA
[by Sung, Jae Jun] Yunovia, a novel drug development subsidiary of Ildong Pharmaceutical Group, announced on June 10 that it will disclose early clinical results of its metabolic disease treatment candidate, ‘ID110521156 (development code),’ at the American Diabetes Association (ADA) meeting scheduled to take place in Chicago, USA, from June 20 to 23 (local time).
ID110521156 is a small-molecule synthetic new drug 라이브 바카라 designed for oral administration. It belongs to the glucagon-like peptide 1 (GLP-1) receptor agonist (RA) class that promotes insulin secretion, regulates blood glucose levels, and suppresses appetite. According to the company, the 라이브 바카라’s differentiation lies in its high productivity and ease of administration, distinguishing it from existing peptide-based treatments, which rely on injections.
Yunovia is currently conducting a multiple ascending dose (MAD) study on the 라이브 바카라 compound, following the completion of a single ascending dose (SAD) study. At the upcoming ADA meeting, the company plans to present a summary of results and key data from the SAD and MAD studies in a poster format.
The company states that the SAD study indicated that ID110521156 tends to produce fewer gastrointestinal side effects than other 라이브 바카라 receptor agonists. In the MAD study, the compound demonstrated a weight loss effect at effective doses without the need for a separate titration process.
“From the early stages of clinical trials, Yunovia has actively collaborated with major overseas 라이브 바카라 companies, aligning its strategy with global trends,” an Ildong 라이브 바카라 Group official said. “We plan to aggressively pursue licensing-out (L/O) opportunities and the discovery of new partners moving forward.”